Maia Biotechnology Inc (MAIA)

$MAIA (NP) Good conversation from Chat (always appreciate when new names that I'm unfamiliar with are raised) I agree on 🚩🚩 Recent press release sounds scammy at first glance: "unmatched efficacy data " "$50 billion immunotherapy market" (poorly run companies often emphasize TAM over anything else) Overpromise, fail to deliver situations or slow trial progress are often signals to steer clear $XBI

$SLS $OSTX $IBRX $MAIA

$MAIA I tried to tell you guy earlier. Don't enter over $1.5-2 if MAIA doesn't have at least 2-3 quarters of runway and Phase 3 is near completion. Even then, it may be risky with so many shares and bonds in management. Bonds in particular. These always come before shares in certain scenarios.

$MAIA Diamond Equity Research These are Paid research reports https://diamondequityresearch.com/company-sponsored-research/ Let that sink in ... Maia is not covered by any (major ) Tier 1 House /Underwriter on the street. Why they cant access LARGE capital for a (LARGE SCALE ) Trial. Partners have only signed product supply agreements. CO is on the hook for those eventually. Piece mill one by one rather than ENROLL SUBSTANTIAL Patients. WITH SO MANY COMPETITORS running Lung Trials .......This is imperative . Meanwhile they took alot of their Cash and put it in BITCOIN TREASURY in hopes to Parlay the cash. Unfortunately Bitcoin has dropped. INSIDERS have bought a discounted share and received a WARRANT many times .......Kinda of a potential small self funding to keep things going ..however HIGH SALARIES still being paid.... dilution comes down the road when and if warrants converted.

$MAIA Diamond Equity Research, an independent equity research firm analysts view MAIA as "well-positioned" scientifically, with a 96-99% Bayesian probability of Phase 3 success based on prior data. Let that sink in!!! https://www.globenewswire.com/news-release/2026/01/20/3221645/0/en/Diamond-Equity-Research-Releases-Update-Note-on-MAIA-Biotechnology-Inc-NYSE-MAIA.html

$MAIA Very important to note the cash burn timing vs interim Phase 3 data release. Interim Phase 3 Data is targeted for 2026 (below). Cash Burn Timing with current cash to last mid-to-late 2026 (below). Stan Smith and team have managed to securing funding on a fund as you need it without exposing MAIA to high dilution or VC control, I think they can fill the gap until the Interim Data is released. Cash Burn MAIA's latest reported cash position was ~$10.9M as of September 30, 2025 (Q3 2025 10-Q), bolstered by ~$17.6M raised throughout 2025 (including a ~$1.51M private placement closed in late December 2025) and a $2.3M NIH grant, with an estimated annual burn rate of ~$15-18M suggesting runway potentially into mid-to-late 2026 without further funding. Interim Phase 3 Interim Phase 3 (THIO-104) efficacy data (e.g., ORR, PFS, DCR) is targeted for 2026 per the company's January 20, 2026 update, which, if positive, could dramatically extend runway via big pharma partnerships, major raises, non-dilutive funding, or accelerated approval paths under Fast Track designation. Summary Positive interim results will "change everything" by attracting big pharma partnerships (leveraging "FAT STACKS OF $$$ AND STOCK" as speculated in posts), non-dilutive funding, or major equity raises, extending runway indefinitely and boosting valuation in the $50B+ immunotherapy market. NFA DYOR

$MAIA February is usually a heavy fundraising month for MAIA. The question now is what will February 2026 look like? MAIA is certainly running low on cash. My best guess is they can probably get to mid-March with their current cash on hand. However, they also have done well raising as needed, and insiders just bought more stock in December. I'm quite positive they have financing lined up. But will this be a large financing deal, or will it continue to be small raises? I honestly don't know, but MAIA needs more cash for their trials, and JPMHCC and Biotech Showcase just ended. Connections were made, the patent cliff is imminent, and there are FAT STACKS OF 💰💰💰💰 AND STOCK that these big pharma companies want to play with. MAIA is VERY well positioned from a science and business standpoint 🥂🪙🥂

$VANI setting up similar to $MAIA in december

$MAIA @telomerase That is a ridiculous rendition of my posts. Some here want to think MAIA released a PR in October about digital do-dads of up to 90% and then did nothing? Everyone gets their own opinion about that - mine has not changed since they did that. Beyond that, Still, no one but me has posted what they think / guess MAIA current cash situation is based on prior Q report - extrapolated burn rate. Its a straightfoward question - what are other's guesses? That all the replies are just hand waving and not a solid number (guess) seems peculiar. Even assume they did not swap their $$$ for BTC or other digital crap. Post your best guess estimate on how much cash you think they currently have. BTW, the flash crash started last week a day after that goofy sponsored youtube video. Ask yourself why a company would do that? One poster suggested they thought its because they MAIA bought (sponsorship) in bulk - Come on!

$MAIA this guy has been stuck in MAIA for over 2years. 09-2024 . Straight fraud loll @MoneyHelix FRAUD. If my maths right ur down over 40% all time HAHAHA.

$MAIA MAIA Quick Facts • Drug: Ateganosine (THIO, 6-thio-2'-deoxyguanosine) – first-in-class telomere-targeting agent that disrupts telomeres in cancer cells via telomerase (active in most cancers). • Mechanism: Incorporates into telomeres of cancer cells, causes rapid damage and death; triggers strong immune responses; sequenced before checkpoint inhibitors to overcome resistance and boost efficacy. • Targets resistant tumors: Designed for patients who fail prior immunotherapy and chemo, with low impact on healthy cells (unlike traditional chemo/radiation). • Clinical status - Phase 2 (THIO-101 in advanced NSCLC, third-line): Highly encouraging results with median OS around 17-18 months (far exceeding standard of care ~5-6 months); PFS ~5-6 months (double SoC); well-tolerated; ongoing expansion (Part C) adding patients and sites in Asia/Europe. • Clinical status - Phase 3 (THIO-104 pivotal trial): Started December 2025 (first patient dosed Dec 11); evaluating ateganosine + checkpoint inhibitor vs. chemo in third-line advanced NSCLC; FDA Fast Track designation accelerates path. • Potential: Strong focus on NSCLC but platform targets telomerase-positive cancers (most solid tumors); could become a key option in immuno-oncology for resistant cases. • 2028 Big Pharma patent cliff advantage: Major oncology blockbusters like Merck's Keytruda (~$25-30B annual sales) face key U.S. patent expirations around 2028, opening huge gaps for novel therapies in post-immunotherapy settings where ateganosine excels. Company: MAIA Biotechnology (NYSE American: MAIA), clinical-stage immuno-oncology firm developing targeted cancer therapies. • Leadership: Founded and led by CEO Vlad Vitoc, M.D.; company name reflects his vision. • Insider alignment: No reported insider sales; recent open-market purchases by CEO and board; directors/officers hold significant stake (~13-14%). • Funding approach: Primarily private placements with strong insider/director participation; no heavy traditional VC influence, preserving control and focus. • IP strength: Robust portfolio with 10+ issued patents worldwide (including recent European grant for analogues and methods); pending applications; potential extensions to 2040s for key claims and next-gen compounds. • Momentum: 2026 milestones include Phase 3 interim readouts, continued FDA engagement, and potential accelerated paths; recent NIH grant and partnerships add validation. • Analyst coverage: Limited but positive — $14 price target from Noble Capital (Outperform rating), implying significant upside on successful Phase 3 execution. • Always DYOR: Check latest from ir.maiabiotech.com, clinicaltrials.gov (NCT05208944 for Phase 2, NCT06908304 for Phase 3), or SEC filings. Exciting small-cap biotech with aligned team and novel approach in a high-need space. The above bullets is information that I gathered for new visitors to quickly get at a glance while filtering out FUD. If you'd like to recommend edits, additions, corrections, or have questions about sources/updates, please reply below when (if) I post this again, happy to refine based on facts! NFA DYOR

$MAIA From 3 to 2, bad days, but we also went from 1.5 to 3. We will test that 3 again, nothing has changed but we can't have news every week either. There will be interim results but could take some time. Meanwhile hodl or add here and there if you believe.

$MAIA thanks for the price panic sellers

$MAIA added, bargain

$MAIA ??

$MAIA this is unbelievably frustrating FFS

$MAIA pos

$MAIA Thanks Psycho, now I can scale back in.

$MAIA Now their money from BITCOIN treasury went down significantly .......because their Cancer program proceeds like a SNAIL😂

$MAIA Added another 650 shares this morning. Looking to buy more later this week if still under $2. 🪙 There is a chance that warrants were exercised in the recent selloffs, but we probably won't know for awhile. Regardless, Phase 3 data is immenent 🥂

$MAIA THE PROMO COMPANY never disappoints ...LOL THE QUARRY OF OVERHEAD on the WARRANTS ....keeps attracting Baggie flies over 2.00 They love it ..... NO CASH to complete LARGE scale trial.......just put out a PR PUMP every now and then that looks<<< impressive. Might get a drug to market by the 30s sometime ....(maybe) but more warrant money to come from newbs.

$MAIA Sometimes there's pain on the way up. Short-term pain, long-term gain. Just bought more, I'm a Believer! https://youtu.be/7wtfhZwyrcc?si=6ng9DuX4jZS3nQPh